APAC Expansion The company is rapidly expanding into Asia, including China and Shanghai, through acquisitions and regional leadership hires. This presents sales opportunities for local regulatory support, CGT manufacturing partnerships, and market-entry consulting for biotechs eyeing China and broader APAC commercialization.

Strategic Partnerships Recent MOUs and collaborations with Altruist Biologics, KunTuo, and Porton Advanced indicate a strong appetite for partner-led development and deployment of CGT capabilities. Leverage these relationships to offer joint programs, accelerated clinical development services, and end-to-end pathway support.

Global Consulting Footprint DHCG combines deep CGT expertise with cross-industry knowledge and regional offices, enabling one-stop advisory across manufacturing, regulatory, quality, and program management. This breadth supports upsell into integrated programs for global tech transfer, process development, and facility design.

Revenue Growth Potential With reported annual revenue in the mid-range tens of millions and a growing client base across biopharma, tools providers, and investors, there is opportunity to expand high-margin consulting services, training, and strategic due diligence for international GMP readiness and market access.

Talent & Capability A mid-sized firm with experienced leadership in CGT, manufacturing, analytics, and regulatory affairs offers a compelling value proposition for clients seeking specialized talent. This can be packaged as scalable engagement models, retainer consulting, and staff augmentation for CGT programs in new regions.